Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Gluco-metabolic effects of oral and intravenous alcohol administration in men

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Mitochondrial mutation m.3243A>G associates with insulin resistance in non-diabetic carriers

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cross-sectional analysis of sleep hours and quality with sex hormones in men

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Replication of newly proposed TNM staging system for medullary thyroid carcinoma: a nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

CONTEXT: Women with polycystic ovary syndrome (PCOS) have an increased risk of cardiovascular disease (CVD), and biomarkers can be used to detect early subclinical CVD. Midregional-pro-adrenomedullin (MR-proADM), midregional-pro-atrial natriuretic peptide (MR-proANP) and copeptin are all associated with CVD and part of the delicate system controlling fluid and hemodynamic homeostasis through vascular tonus and diuresis. The GLP-1 receptor agonist liraglutide, developed for treatment of type 2 diabetes (T2D), improves cardiovascular outcomes in patients with T2D including a decrease in particular MR-proANP.

OBJECTIVE: To investigate if treatment with liraglutide in women with PCOS reduces levels of the cardiovascular biomarkers MR-proADM, MR-proANP and copeptin.

METHODS: Seventy-two overweight women with PCOS were treated with 1.8 mg/day liraglutide or placebo for 26 weeks in a placebo-controlled RCT. Biomarkers, anthropometrics, insulin resistance, body composition (DXA) and visceral fat (MRI) were examined.

RESULTS: Baseline median (IQR) levels were as follows: MR-proADM 0.52 (0.45-0.56) nmol/L, MR-proANP 44.8 (34.6-56.7) pmol/L and copeptin 4.95 (3.50-6.50) pmol/L. Mean percentage differences (95% CI) between liraglutide and placebo group after treatment were as follows: MR-proADM -6% (-11 to 2, P = 0.058), MR-proANP -25% (-37 to -11, P = 0.001) and copeptin +4% (-13 to 25, P = 0.64). Reduction in MR-proANP concentration correlated with both increased heart rate and diastolic blood pressure in the liraglutide group. Multiple regression analyses with adjustment for BMI, free testosterone, insulin resistance, visceral fat, heart rate and eGFR showed reductions in MR-proANP to be independently correlated with an increase in the heart rate.

CONCLUSION: In an RCT, liraglutide treatment in women with PCOS reduced levels of the cardiovascular risk biomarkers MR-proANP with 25% and MR-proADM with 6% (borderline significance) compared with placebo. The decrease in MR-proANP was independently associated with an increase in the heart rate.

Original languageEnglish
JournalEndocrine Connections
Volume7
Issue number1
Pages (from-to)115-123
Number of pages9
ISSN2049-3614
DOIs
Publication statusPublished - Jan 2018

    Research areas

  • Journal Article

ID: 52541849